NAD dyshomeostasis drives muscle bioenergetic dysfunction
PrimaryNADMED-linked measurements support the theory that disrupted NAD and NADP redox balance can mark, and potentially contribute to, bioenergetic impairment in age-relevant muscle disease contexts. In RYR1-related myopathies, affected individuals showed systemic NAD+ deficiency, elevated NADPH, and reduced NAD+/NADH and NADP/NADPH ratios in subsets of patients, consistent with disturbed cellular metabolism and redox homeostasis. A testable prediction is that patients or tissues with lower NAD+ or altered NAD/NADH and NADP/NADPH ratios should show worse mitochondrial respiration or ATP production. The same study reports that nicotinamide riboside increased cellular NAD+ in patient-derived myotubes and favorably modified maximal respiration and ATP production, supporting the hypothesis that NAD+ repletion could be therapeutically relevant in neuromuscular disorders associated with bioenergetic deficits, including sarcopenia-adjacent mechanisms.
Popperian evaluation
The premise is credible: NAD+ and NADP sit directly inside cellular redox and energy metabolism, and the RYR1-related myopathy study reports a measurable pattern, 19/28 affected individuals with NAD+ below 21 µM, 22/26 with NADPH above 1.6 µM, and reduced NAD+/NADH or NADP/NADPH ratios in patient subsets. The weak spot is tissue mapping. Whole-blood NAD metabolites may track disease biology, but they do not automatically prove muscle-cell redox failure.
Supporting evidence: RYR1-related myopathy patients showed systemic NAD+ deficiency in 19/28 cases.; Affected individuals frequently showed elevated NADPH, 22/26 above 1.6 µM.; Patient-derived myotubes responded to nicotinamide riboside with higher cellular NAD+ and improved respiration-related readouts.
Counter evidence: Reduced NAD+/NADH was present in 9/28 individuals, so the signal is incomplete across the cohort.; Ryr1 Y524S specimens did not show the same redox imbalance.; Whole-blood NAD measurements may not cleanly reflect skeletal muscle redox state.
The theory explains a coherent slice of the evidence: low NAD+, high NADPH, altered redox ratios, and weaker mitochondrial output can belong to the same metabolic failure pattern. The nicotinamide riboside myotube result gives the causal story some bite because raising NAD+ changed maximal respiration and ATP production. Still, RYR1 disease starts with calcium dysregulation, so NAD dyshomeostasis may be downstream damage, a compensatory response, or a parallel marker rather than the driver.
Supporting evidence: The same RYR1-related myopathy study links NAD+ deficiency, NADPH elevation, altered redox ratios, and bioenergetic measures.; Nicotinamide riboside increased NAD+ in patient-derived myotubes and favorably modified maximal respiration and ATP production.; Human adipocyte data show that redox imbalance can travel with reduced oxidative phosphorylation and mitochondrial metabolic reprogramming.
Counter evidence: RYR1-related myopathies have a known calcium-handling defect that could explain mitochondrial stress upstream of NAD changes.; The adipocyte evidence comes from high-glucose culture conditions, not muscle disease.; The current evidence does not show that NAD changes precede bioenergetic dysfunction in patients.
The theory is testable in a real Popperian sense. It predicts that lower NAD+ or altered NAD+/NADH and NADP/NADPH ratios should track with worse mitochondrial respiration or ATP production, and that NAD+ repletion should improve those outputs. A clean failure would hurt the theory: matched muscle samples with abnormal NAD metrics but normal respiration, or NAD+ restoration without bioenergetic improvement, would argue against the driver claim.
Supporting evidence: The theory names measurable variables: NAD+, NADH, NADP, NADPH, redox ratios, mitochondrial respiration, and ATP production.; The theory makes a directional prediction: worse redox imbalance should associate with worse mitochondrial performance.; The nicotinamide riboside experiment gives an intervention test rather than only a correlation.
Counter evidence: The prediction still needs sharper thresholds for what counts as a failed bioenergetic response.; Patient heterogeneity could blur falsification unless studies stratify by genotype, disease severity, tissue, and treatment exposure.; Blood and muscle measurements may disagree, which could make some tests hard to interpret.
Reasoning tree
Public endorsements
She is publicly tied to NADMED, and she talks about metabolism as a core biomedical theme plus careful, titrated supplementation. But the provided public material does not show her explicitly endorsing the specific claim that NAD dyshomeostasis drives muscle bioenergetic dysfunction in age-relevant muscle disease. It is adjacent, not explicit.
Evidence publication IDs: 161fcd85-2afe-4dae-a7ab-f41f412f1d53, 27e22c9a-f3fa-4275-ab0b-74c9b1c2f0d7
The provided evidence does not show this James Lee discussing NADMED, NAD redox balance, muscle bioenergetics, RYR1 myopathies, or nicotinamide riboside. The quotes are about enterprise AI, product retention, and a separate aging-services remark, and at least one appears likely to refer to a different James Lee. On this record, there is no public endorsement, mention, or contradiction of the theory.
Jana Buzkova publicly discusses NAD measurement and metabolism in aging, and she is listed as a coauthor and NADMED cofounder on a NADMED-linked preprint about blood NAD and glutathione dynamics. That supports a public association with the broader NAD/redox-metabolism thesis. The dossier does not show a direct public statement from her explicitly backing the narrower theory that NAD dyshomeostasis drives muscle bioenergetic dysfunction in age-relevant muscle disease, so this is a mention rather than a clear endorsement.
Evidence publication IDs: aff24f44-ba90-469f-8d2f-5fb42bd4dd70
No public quotes, records, or publications are provided that tie Juha Tuominen to this theory. With no evidence of endorsement, mention, or contradiction, the supported label is silence.